ArticleScientific reports2025
Impact of dexmedetomidine administration on mortality in patients with cardiac arrest: a propensity score matching analysis of the MIMIC-IV database.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dexmedetomidine (DEX), a selective α2-adrenoceptor agonist, is used in critical care for sedation and sympathetic modulation. However, its association with survival after cardiac arrest remains uncertain.This study investigated the relationship between DEX administration and mortality risk in cardiac arrest patients.This retrospective cohort study utilized the MIMIC-IV database. Adult patients with documented cardiac arrest (as defined by ICD-9/10 codes) prior to intensive care unit (ICU) admission were stratified into DEX-exposed and unexposed groups based on dexmedetomidine administration. The primary outcome was 28-day mortality; secondary endpoints were 90-day and 1-year mortality. Patients were matched 1:1 using propensity score matching (PSM) based on key baseline characteristics such as demographics, comorbidities, and illness severity scores to minimize confounding. Robustness was assessed through sensitivity analyses and adjusted multivariable Cox regression. Among 1,342 patients, 314 (23.4%) received DEX. After PSM (269 matched pairs), DEX exposure were associated with significantly lower mortality rates at 28 days (90/269 [33.5%] vs. 150/269 [55.8%]), 90 days (112/269 [41.6%] vs. 165/269 [61.3%]), and 1 year (128/269 [47.6%] vs. 180/269 [66.9%]). Multivariable analysis showed DEX administration was independently associated with lower mortality at 28-day (HR 0.36, 95% CI 0.27-0.48, p < 0.001), 90-day (HR 0.42, 95% CI 0.32-0.54, p < 0.001), and 1-year (HR 0.44, 95% CI 0.34-0.56, p < 0.001). These associations remained consistent across sensitivity analyses and subgroups stratified by gender, age, comorbidity burden, and illness severity scores. DEX administration demonstrated a significant association with improved survival in post-cardiac arrest patients, suggesting a potential role in post-cardiac arrest management. Prospective studies are warranted to confirm its clinical efficacy and safety in post-arrest management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.